NLRP3 inflammasome pathways in atherosclerosis
- PMID: 29126031
- DOI: 10.1016/j.atherosclerosis.2017.10.027
NLRP3 inflammasome pathways in atherosclerosis
Abstract
Atherosclerosis is the major cause of death and disability. Atherosclerotic plaques are characterized by a chronic sterile inflammation in the large blood vessels, where lipid-derived and damage-associated molecular patterns play important roles in inciting immune responses. Following the initial demonstration that NLR family Pyrin domain containing 3 (NLRP3) was important for atherogenesis, a substantial number of studies have emerged addressing the basic mechanisms of inflammasome activation and their relevance to atherosclerosis. In this review, we introduce the basic cellular and molecular mechanisms of NLRP3 inflammasome activation, and discuss the current findings and therapeutic strategies that target NLRP3 inflammasome activation during the development and progression of atherosclerosis.
Keywords: ASC; Atherosclerosis; Caspase-1; IL-1β; NLRP3 inflammasome.
Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis.Circulation. 2018 Aug 28;138(9):898-912. doi: 10.1161/CIRCULATIONAHA.117.032636. Circulation. 2018. PMID: 29588315 Free PMC article.
-
Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis.PLoS One. 2014 Jan 27;9(1):e87552. doi: 10.1371/journal.pone.0087552. eCollection 2014. PLoS One. 2014. PMID: 24475307 Free PMC article.
-
Vascular endothelial cells senescence is associated with NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome activation via reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP) pathway.Int J Biochem Cell Biol. 2017 Mar;84:22-34. doi: 10.1016/j.biocel.2017.01.001. Epub 2017 Jan 4. Int J Biochem Cell Biol. 2017. PMID: 28064010
-
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.Circ Res. 2018 Jun 8;122(12):1722-1740. doi: 10.1161/CIRCRESAHA.118.311362. Circ Res. 2018. PMID: 29880500 Review.
-
[Advances in mechanisms for NLRP3 inflammasomes regulation].Yao Xue Xue Bao. 2016 Oct;51(10):1505-12. Yao Xue Xue Bao. 2016. PMID: 29924571 Review. Chinese.
Cited by
-
TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells.Int J Mol Sci. 2021 May 5;22(9):4875. doi: 10.3390/ijms22094875. Int J Mol Sci. 2021. PMID: 34062977 Free PMC article.
-
Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and Disease.Int J Mol Sci. 2020 Jun 23;21(12):4459. doi: 10.3390/ijms21124459. Int J Mol Sci. 2020. PMID: 32585928 Free PMC article. Review.
-
Liquefaction of the Brain following Stroke Shares a Similar Molecular and Morphological Profile with Atherosclerosis and Mediates Secondary Neurodegeneration in an Osteopontin-Dependent Mechanism.eNeuro. 2018 Nov 8;5(5):ENEURO.0076-18.2018. doi: 10.1523/ENEURO.0076-18.2018. eCollection 2018 Sep-Oct. eNeuro. 2018. PMID: 30417081 Free PMC article.
-
Potential Therapeutic Applications of Hydrogen in Chronic Inflammatory Diseases: Possible Inhibiting Role on Mitochondrial Stress.Int J Mol Sci. 2021 Mar 4;22(5):2549. doi: 10.3390/ijms22052549. Int J Mol Sci. 2021. PMID: 33806292 Free PMC article. Review.
-
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis.Ann Med. 2023;55(2):2304667. doi: 10.1080/07853890.2024.2304667. Epub 2024 Jan 17. Ann Med. 2023. PMID: 38233735 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
